Bruce Cozadd Sells 6,000 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the sale, the director directly owned 366,682 shares of the company’s stock, valued at $88,176,020.54. This represents a 1.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

Jazz Pharmaceuticals stock traded up $0.70 during midday trading on Monday, hitting $244.17. 861,484 shares of the company’s stock were exchanged, compared to its average volume of 983,015. The company has a market cap of $15.34 billion, a P/E ratio of -12,202.40, a PEG ratio of 0.21 and a beta of 0.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The stock has a 50-day moving average price of $228.38 and a two-hundred day moving average price of $195.43. Jazz Pharmaceuticals PLC has a 52-week low of $105.00 and a 52-week high of $246.07.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The firm had revenue of $1.07 billion for the quarter. On average, equities research analysts forecast that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the stock. Leerink Partners lifted their target price on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a research report on Wednesday, April 22nd. Sanford C. Bernstein restated a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. Morgan Stanley reaffirmed an “overweight” rating and set a $245.00 price objective on shares of Jazz Pharmaceuticals in a report on Thursday, May 7th. Barclays upped their target price on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 27th. Finally, Raymond James Financial reissued an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Sixteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $246.06.

Institutional Trading of Jazz Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Hilltop National Bank bought a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $36,000. LRI Investments LLC purchased a new stake in Jazz Pharmaceuticals during the 4th quarter valued at about $38,000. Danske Bank A S purchased a new stake in Jazz Pharmaceuticals during the 3rd quarter valued at about $40,000. Geneos Wealth Management Inc. grew its position in Jazz Pharmaceuticals by 57.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the last quarter. Finally, Caitong International Asset Management Co. Ltd increased its stake in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after purchasing an additional 332 shares during the period. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.